Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients

• Published in: Photochemical & photobiological sciences Vol. 10; no. 5; pp. 817 - 821
• Main Authors: Li, Xiaosong, Ferrel, Gabriela L., Guerra, Maria C., Hode, Tomas, Lunn, John A., Adalsteinsson, Orn, Nordquist, Robert E., Liu, Hong, Chen, Wei R.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2011
• Subjects: Adult; Aged; Aged, 80 and over; Biochemistry; Biomaterials; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Chemistry; Chitosan - immunology; Female; Humans; Immunotherapy - adverse effects; Indocyanine Green - chemistry; Lasers; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Physical Chemistry; Plant Sciences; Tomography, X-Ray Computed
• ISSN: 1474-905X; 1474-9092
• DOI: 10.1039/c0pp00306a

We report our preliminary results of a pilot clinical trial of late-stage breast cancer patients treated by laser immunotherapy (LIT), a local intervention using an 805 nm laser for non-invasive irradiation, indocyanine green for selective thermal effect, and immunoadjuvant (glycated chitosan) for immunological stimulation. Ten breast cancer patients were enrolled in this study; all patients were considered to be out of other available treatment options. Toxicity was individually evaluated through physical exams and laboratory tests. Adverse reactions only occurred in the area of treatment due to photothermal injury and local administration of immunoadjuvant. No grade 3 or 4 side effects were observed. Treatment efficacy of LIT was also evaluated by physical examination and tomography. In 8 patients available for evaluation, the objective response rate was 62.5% and the clinical beneficial response rate was 75%. While the study is still ongoing, the initial outcomes of this clinical trial show that LIT is well tolerated and is promising in the treatment of metastatic breast cancer.